Navigation Links
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
Date:11/2/2008

Novartis notified of data set closing, Top-line results expected in

November

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic drug. CTI plans to report top-line results in November.

"We are excited to have reached the end of the treatment phase and follow-up period for the pixantrone pivotal study and look forward to reporting top-line results in November," said James A. Bianco, M.D., CEO of Cell Therapeutics. "Complete remissions in this patient population with end stage advanced disease are seldom accomplished with the current standard of care. Pixantrone, if successful in achieving the study objectives, could offer these patients a significant benefit, and we would work with the FDA to submit an NDA in 2009."

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
5. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
6. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
7. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
10. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
11. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... , May 29, 2015 Educating the ... the Association for the Advancement of Wound Care ... With support from AAWC,s corporate partners, the Association ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ ... care pathway with links to various CME/CEU educational ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2
... Findings from an international Phase 3 clinical trial of the ... and effective at restoring continence when worn up to 12 ... 87% of users rated the ability of the device to ... study results published in the British Journal of Nursing ...
... HONG KONG, Sept. 28, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, today ... ownership in its NYSE-listed affiliate, China Cord Blood Corporation ... result of which the Group now owns 40.9% of ...
Cached Medicine Technology:Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 2Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial 3Golden Meditech Increase Stake in NYSE-listed Affiliate - China Cord Blood Corporation to 40.9% 2
(Date:5/30/2015)... the Snail ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... Interactive mobile games for children have become quite popular these ... playing are doing much for their intellectual development. However, there’s ...
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a ... hanging signs ; making what was formerly an elite ... ceiling rigging points at a usual height of 16’-20’ are ... These signs are very unique and more visible than the ... and dismantle labor and rigging the costs far outweigh the ...
(Date:5/29/2015)... What does community do? , According to ... together to plant gardens, to teach young people, to ... critical issues. Community invites everyone to help improve lives ... Community Does" was commissioned by The Denver Foundation, the ... during the foundation’s Annual Celebration in May. At just ...
(Date:5/29/2015)... Cincinnati, Ohio (PRWEB) May 29, 2015 ... Proven Experience to Cincinnati , The Department of Veterans ... John A. Gennaro as the new director of the ... of health care to more than 43,000 unique Veterans ... , With over 2,000 staff, CVAMC is a two-division ...
(Date:5/29/2015)... May 29, 2015 Dot Hill can mark one ... resident of Lake Prince Woods retirement community is the ... Virginia Beach, Virginia. , “It was great fun!”, she exclaimed. ... didn’t want me to so they thought this would be ok.” ... into a vertical wind tunnel,” she described. “I don’t remember ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Indoor Skydiving Brings Thrills to Seniors 2
... Research shows canines can count, learn words , MONDAY, ... the beloved family dog is really a toddler with ... developmental abilities equivalent to a human 2-year-old," said dog ... canine research developments at the American Psychological Association annual ...
... , The National Comprehensive Cancer Network (NCCN) recently ... the results of the recent ERSPC trial that assessed the ... screening does save lives when performed intelligently in men at ... FORT WASHINGTON, Pa., Aug. 10 Prostate-Specific Antigen (PSA) ...
... AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging ... develop novel formulations of drugs, is pleased to ... patent in China for its topical platform technology ... The platform is an integral part of the ...
... , , NEW YORK, ... CRE ) ("Care" or the "Company"), a real estate investment and finance ... today reported financial results for the second quarter ended June 30, 2009. ... GAAP of $0.5 million, or $0.03 per basic and diluted share. ...
... ROCHESTER, N.Y., Aug. 10 Your sleeping problems might be ... (FM), and Chronic Fatigue Syndrome (CFS). But it can also be ... , , Recent studies show that chronic infection ... by Professor Mark Opp from the University of Michigan Medical School ...
... Aug. 10 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... Western,healthcare products and services in the People,s Republic of ... exclusive, multi-year distribution,agreements for China with Biotest AG and ... based in Dreieich, Germany (SDAX: BIO3), specializes in,innovative hematology ...
Cached Medicine News:Health News:Dogs and 2-Year-Olds on Same Mental Plane 2Health News:Dogs and 2-Year-Olds on Same Mental Plane 3Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 2Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 3Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 4Health News:NCCN Stresses Importance of PSA Testing in High-Risk Men 5Health News:AlphaRx Receives China Patent on Its Drug Delivery Platform 2Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 2Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 3Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 4Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 5Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 6Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 7Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 8Health News:Care Investment Trust Inc. Announces Second Quarter 2009 Results 9Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 4
Papavero-caspar specula for trans-sphenoidal hypophysectomy....
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Fahlbusch hypophysectomie instrument, spoon, bayonet-shaped, malleable....
Cushing pituitary scoop, malleable, silver-plated....
Medicine Products: